Journal: Antibiotics

Article Title: Microbiological Assessment of the FilmArray Blood Culture Identification 2 Panel: Potential Impact in Critically Ill Patients

doi: 10.3390/antibiotics12081247

Figure Lengend Snippet: Summary of targets available for testing on the BioFire FilmArray BCID2 panel.

Article Snippet: Multiplex PCR platforms are available for this purpose, and in the context of BSI, the BioFire FilmArray Blood Culture ID (BCID) has been proved to be a powerful tool.

Techniques:

Journal: Open Forum Infectious Diseases

Article Title: Impact of a Multiplex PCR Assay for Bloodstream Infections With and Without Antimicrobial Stewardship Intervention at a Cancer Hospital

doi: 10.1093/ofid/ofy258

Figure Lengend Snippet: Flow diagram for participants included in the study. Unadjusted mean time to appropriate antimicrobial therapy using a 1-way analysis of variance test as a comparison: no statistical difference in uncontrolled means between PRE, POST, and POST-AS groups (44 hours, 25 hours, 26 hours; P = .069) at an alpha = .05 level. Abbreviations: BCID, multiplex polymerase chain reaction–based blood culture identification; BSI, bloodstream infection; PRE, before BCID implementation; OSH, outside hospital; POST, after BCID implementation; POST-AS, BCID coupled with antimicrobial stewardship.

Article Snippet: Biofire FilmArray Multiplex PCR BCID was implemented in November 2014 without AS intervention, followed by AS notification of results and active guidance on therapy communicated to providers in October 2016.

Techniques: Multiplex Assay, Polymerase Chain Reaction, Infection

Journal: Missouri Medicine

Article Title: Updates on Rapid Diagnostic Tests in Infectious Diseases

doi:

Figure Lengend Snippet: Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels

Article Snippet: There are currently four FDA-cleared molecular multiplex assays for blood culture pathogen identification: FilmArray BCID panel (bioMérieux, Marcy l’Etoile, France), Verigene Gram Positive Blood Culture ID assay (BCID-GP) and Gram Negative Blood Culture ID assay (BCID-GN) (Luminex Molecular Diagnostics, Toronto, Canada), Accelerate PhenoTest BC kit (Accelerate Diagnostics, Tucson, AZ), and ePlex Blood Culture Identification Gram-Positive Panel (BCID-GP) and Gram-Negative Panel (BCID-GN) (GenMark Diagnostics, Carlsbad, CA).

Techniques: Multiplex Assay, Bla VIM Assay

Journal: Missouri Medicine

Article Title: Updates on Rapid Diagnostic Tests in Infectious Diseases

doi:

Figure Lengend Snippet: Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels

Article Snippet: There are currently four FDA-cleared molecular multiplex assays for blood culture pathogen identification: FilmArray BCID panel (bioMérieux, Marcy l’Etoile, France), Verigene Gram Positive Blood Culture ID assay (BCID-GP) and Gram Negative Blood Culture ID assay (BCID-GN) (Luminex Molecular Diagnostics, Toronto, Canada), Accelerate PhenoTest BC kit (Accelerate Diagnostics, Tucson, AZ), and ePlex Blood Culture Identification Gram-Positive Panel (BCID-GP) and Gram-Negative Panel (BCID-GN) (GenMark Diagnostics, Carlsbad, CA).

Techniques: Multiplex Assay, Bla VIM Assay

Journal: Frontiers in Microbiology

Article Title: Clinical metagenomics—challenges and future prospects

doi: 10.3389/fmicb.2023.1186424

Figure Lengend Snippet: Routine diagnostic assays in a clinical setting for the detection of pathogens.

Article Snippet: Multiplex PCR , Biofire Diagnostics, GenMark Diagnostics , FilmArray BCID, ePlex BCID , 1–1.5 h , Gram-negative bacteria , .

Techniques: Diagnostic Assay, Multiplex Assay, Luminex, Nuclear Magnetic Resonance, Low Copy Number